Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 15/20 | 1.00 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152210 | 0.93 | CCKAR (1.00) | CCKARMT-CO1CNR2 | |
| SCHEMBL2152958 | 0.91 | CCKAR (0.84) | CCKAR | |
| SCHEMBL12510286 | 0.91 | CCKAR (0.83) | CCKAR | |
| SCHEMBL2913085 | 0.88 | CCKAR (0.79) | CCKARMT-CO1CNR2 | |
| SCHEMBL3128347 | 0.88 | CCKAR (0.85) | CCKAR | |
| SCHEMBL2152165 | 0.88 | CCKAR (0.78) | CCKAR | |
| SCHEMBL2152839 | 0.87 | CCKAR (1.00) | CCKARMT-CO1CNR2 | |
| SCHEMBL2913088 | 0.86 | CCKAR (0.75) | CCKAR | |
| SCHEMBL502707 | 0.82 | CCKAR (1.00) | CCKAR | |
| SCHEMBL3125889 | 0.81 | CCKAR (1.00) | CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010519-B1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-06 | — | — | EP | claimed |
| US-7795265-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | claimed |
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | claimed |
| EP-2010519-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
| EP-2906040-B1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2888007-B1 | BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2887807-B1 | BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2008039327-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039418-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120688-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244048-A1 | Neuromedin U receptor agonists and uses thereof | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| WO-2007064566-A2 | HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007041052-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GPR119 | CCKAR 1/4885MT-CO1 1798/4885CNR2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.